Related by context. All words. (Click for frequent words.) 72 recurrent NSCLC 72 metastatic RCC 72 advanced unresectable 72 metastatic renal cell carcinoma 71 non squamous 70 unresectable 70 metastatic GIST 70 stage IIIB 69 KRAS mutations occur 69 IV NSCLC 69 resectable 69 PREZISTA r 69 malignant pleural mesothelioma 69 recurrent glioblastoma multiforme 69 mRCC 68 HER2 positive metastatic breast 68 metastatic NSCLC 68 Amrubicin 68 Hepatocellular Carcinoma HCC 68 Navelbine ® 68 neoadjuvant therapy 68 stage IIIB IV 68 stage IIIb IV 68 Pemetrexed 67 non metastatic osteosarcoma 67 CIMZIA ™ 67 fallopian tube carcinoma 67 DOXIL 67 docetaxel chemotherapy 67 taxane chemotherapy 67 chemoradiotherapy 67 gefitinib Iressa 67 anthracycline taxane 67 FOLFIRI 67 Gliadel Wafer 67 nonsmall cell lung cancer 67 trabectedin 67 recurrent metastatic 67 relapsed MM 67 Doxil ® 67 metastatic gastric 67 ELOXATIN 67 preoperative chemotherapy 67 dacarbazine 67 unresectable locally advanced 67 dacarbazine chemotherapy 67 differentiated thyroid 67 CANCIDAS 67 FOLFOX4 66 chemoradiation therapy 66 relapsed SCLC 66 metastatic CRC 66 clinically localized prostate 66 pazopanib 66 severe neutropenia 66 ZACTIMA 66 biologic DMARD 66 gemcitabine chemotherapy 66 HBeAg negative 66 sorafenib tablets 66 cisplatin chemotherapy 66 Torisel 66 APTIVUS r 66 infusional 5-FU/LV 66 intravenous bisphosphonates 66 bevacizumab Avastin 66 docetaxel Taxotere ® 66 Fludara 66 colorectal liver metastases 66 platinum refractory 66 paclitaxel carboplatin 66 alpha interferons 66 TEMODAL 66 metastatic malignant 66 temsirolimus 66 AVOREN 66 sunitinib malate 66 squamous 66 neoadjuvant 66 situ CIS 66 FOLFOX6 66 curative resection 65 trastuzumab Herceptin ® 65 sorafenib Nexavar 65 nonmetastatic 65 5-FU/LV 65 erlotinib Tarceva ® 65 squamous cell histology 65 mCRC patients 65 efalizumab 65 gastrointestinal stromal tumors 65 carboplatin paclitaxel 65 fluoropyrimidine 65 IRESSA 65 Taxotere ® 65 ORENCIA ® 65 SCCHN 65 ritonavir boosted protease inhibitor 65 TYKERB 65 stage IIIA 65 lenalidomide Revlimid R 65 vinorelbine 65 Faslodex 65 GAMMAGARD 65 refractory multiple myeloma 65 Bevacizumab 65 imatinib mesylate 65 OPAXIO 65 metastatic HER2 positive 65 eribulin mesylate 65 standard chemotherapy regimen 65 basal cell carcinoma BCC 65 TORISEL 65 Xelox 65 GISTs 65 cytotoxic therapy 65 adjuvant radiation 65 PEGINTRON TM 65 proliferative diabetic retinopathy 65 proliferative retinopathy 65 PegIntron 65 epithelial tumors 65 advanced adenomas 65 HNSCC 65 metastatic colorectal 65 Surgical resection 65 CAELYX 65 XIENCE V PROMUS Stent 65 Hycamtin ® 65 Velcade bortezomib 65 histologically confirmed 65 metastatic colorectal cancer 65 gastrointestinal stromal tumor GIST 65 protease inhibitor PI 65 hepatocellular cancer 65 ribavirin therapy 65 chemotherapy cisplatin 65 metastatic castrate resistant 65 histological subtype 65 VFEND 65 cytotoxic chemotherapy 65 ARIXTRA 65 vandetanib 64 metastatic pancreatic cancer 64 Nexavar sorafenib 64 Renal Cell Carcinoma RCC 64 AGILECT R 64 virologic failure 64 CTEPH 64 ZYVOX 64 unresectable tumors 64 invasive candidiasis 64 mycophenolate mofetil 64 PNH patients 64 Fludara ® 64 sirolimus stent 64 metastatic hormone refractory 64 pancreatic adenocarcinoma 64 VELCADE melphalan 64 TTF Therapy 64 macroalbuminuria 64 metastatic HRPC 64 XGEVA 64 KRAS wild 64 docetaxel Taxotere 64 candidemia 64 melphalan prednisone 64 CHOP chemotherapy 64 pegylated liposomal doxorubicin 64 Platinol ® cisplatin 64 dopamine partial agonist 64 medically inoperable 64 dacarbazine DTIC 64 follicular lymphoma FL 64 mcg albinterferon alfa 2b 64 Hodgkin lymphoma HL 64 Mitoxantrone 64 peginterferon alfa 2a Pegasys 64 NATRECOR ® 64 gastrointestinal stromal tumors GIST 64 symptomatic BPH 64 sunitinib 64 metastatic renal cell 64 plus gemcitabine 64 squamous histology 64 alemtuzumab treated 64 flutamide 64 KRAS status 64 ARCOXIA 64 forodesine 64 completely resected 64 oral antidiabetic medication 64 SHPT 64 Squamous 64 MAGE A3 ASCI 64 CTAP# Capsules 64 SCIg 64 ARB telmisartan 64 myelodysplastic myeloproliferative diseases 64 bevacizumab Avastin ® 64 histologic subtype 64 cervical carcinoma 64 CINTREDEKIN BESUDOTOX 64 interferon gamma 1b 64 rFVIIa 64 NATRECOR R 64 metastatic castration resistant 64 biochemical recurrence 64 BRIM2 64 hepatocellular carcinomas 64 Folfox 64 grade cervical intraepithelial 64 nonmelanoma skin cancers 64 AVASTIN 64 adenomatous polyps 64 Erlotinib 64 HBV infections 64 DMARD 64 pimecrolimus 64 neoadjuvant chemotherapy 64 aleglitazar 64 chlorambucil 64 renal dysfunction 64 MGd 64 posaconazole 64 chemotherapeutic regimens 64 romiplostim 64 hypercalcemia 64 distant metastasis 64 Raptiva ® 64 CIN3 64 fluvastatin 64 CIMZIA TM certolizumab pegol 64 ritonavir boosted 64 abacavir Ziagen 64 Neovascular AMD 64 advanced hepatocellular carcinoma 64 receptor tyrosine kinase inhibitor 64 panitumumab Vectibix 64 radiochemotherapy 64 hepatic metastases 64 vincristine doxorubicin 64 Taxotere R 63 paclitaxel Taxol 63 gemcitabine carboplatin 63 YONDELIS 63 bendamustine 63 pegfilgrastim 63 ancrod 63 axitinib 63 advanced metastatic renal 63 soft tissue sarcomas 63 RRMS patients 63 TYGACIL 63 refractory metastatic colorectal cancer 63 hematologic toxicity 63 Tamibarotene 63 fluorouracil 63 FROVA 63 nucleoside analogue 63 cytoreductive nephrectomy 63 EGFR TKI 63 skeletal metastases 63 BARACLUDE ® 63 metastatic neuroendocrine tumors 63 tocilizumab 63 QuadraSphere 63 neoadjuvant treatment 63 INCB# [003] 63 receiving prophylactic anticoagulation 63 metastatic lung cancer 63 locoregional 63 oral iron chelator 63 severe hypersensitivity reactions 63 low dose cytarabine 63 thoracoscopic lobectomy 63 IV tPA 63 chemoembolization 63 colorectal cancer CRC 63 cinacalcet 63 comparator arm 63 heavily pretreated patients 63 pancreatic NET 63 adult chronic ITP 63 doxorubicin HCl liposome injection 63 cetuximab Erbitux R 63 essential thrombocythemia 63 Ophena TM 63 cetuximab Erbitux ® 63 liver metastases 63 renal cell carcinoma 63 phase IIb clinical 63 INC# 63 haematologic 63 Allovectin 7 ® 63 dasatinib Sprycel ® 63 TMP SMX 63 immunomodulatory therapy 63 CYT# potent vascular disrupting 63 colorectal cancer liver metastases 63 Hycamtin 63 Serious adverse reactions 63 NeuroStar TMS Therapy 63 PSA nadir 63 hepatorenal syndrome 63 relapsing MS 63 chronic periodontitis 63 MYLOTARG 63 hepatocellular carcinoma HCC 63 postoperative chemotherapy 63 fingolimod 63 interferon alfa 63 Trastuzumab 63 thromboembolic events 63 ZOLINZA 63 advanced adenoma 63 recurrent GBM 63 genotypic resistance 63 TNF antagonists 63 marketed pegylated interferons 63 adjuvant radiotherapy 63 crizotinib PF # 63 specific antigen PSA 63 oral ridaforolimus 63 Gemzar ® 63 Tarceva TM 63 oral Hycamtin 63 Paraplatin ® 63 severe renal impairment 63 external beam radiotherapy 63 malignant neoplasms 63 FOLFOX regimen 63 salmeterol fluticasone 63 MIRCERA 63 teriflunomide 63 QTc prolongation 63 definite stent thrombosis 63 dosing cohort 63 LV dysfunction 63 carcinoid tumors 63 pain palliation 63 chemotherapeutic regimen 63 myelodysplastic syndrome MDS 63 FluCAM 63 peritumoral brain edema 63 ICD implantation 63 intracranial hemorrhage ICH 63 tigecycline 63 Xeloda capecitabine 63 5 Fluorouracil 63 Actimmune ® 63 peginterferon alfa 63 gemcitabine Gemzar 63 calcineurin inhibitors 63 alteplase 63 hormone refractory prostate cancer 63 Xanafide 63 Advanced Renal Cell 63 cediranib 63 refractory metastatic 63 gadobutrol 63 terlipressin 63 androgen deprivation 63 seminoma 63 NEUPOGEN 63 gastrointestinal stromal tumor 63 vismodegib 63 HBeAg positive patients 63 leukemia AML 63 estramustine 63 advanced NSCLC 63 cancer mCRC 62 Diabetic Macular Edema 62 standard chemotherapy regimens 62 FASLODEX 62 Diovan HCT 62 FIRMAGON 62 superficial bladder cancer 62 VaD 62 MabCampath 62 cetuximab Erbitux 62 oral FTY# 62 Votrient 62 methotrexate therapy 62 paclitaxel Taxol ® 62 octreotide LAR 62 Cytoxan 62 PROLARIS 62 HER2 overexpression 62 Halaven 62 ALT flares 62 fallopian tube cancers 62 tumors GIST 62 lanthanum carbonate 62 Irinotecan 62 secondary hyperparathyroidism 62 APTIVUS ritonavir 62 evaluating tivozanib 62 HBeAg positive 62 alkylating agent 62 TAXOTERE R 62 INTELENCE 62 Traficet EN 62 CIN2 + 62 underwent resection 62 goserelin 62 pheochromocytoma 62 irinotecan chemotherapy 62 Vicinium TM 62 Elitek 62 anti angiogenic therapy 62 Betaferon ® 62 anthracyclines taxanes 62 preoperative radiotherapy 62 opioid induced constipation OIC 62 ER CHOP 62 bronchogenic carcinoma 62 SJIA 62 elevated LDH 62 luteinizing hormone releasing 62 Tarceva erlotinib 62 Sanofi Aventis Taxotere 62 chemoradiation 62 HBeAg negative patients 62 elevated serum creatinine 62 CMV disease 62 paclitaxel Taxol R 62 bone metastases 62 assessing T DM1 62 vWD 62 novel VDA molecule 62 paclitaxel eluting stents 62 adjuvant therapy 62 Cutaneous T 62 zotarolimus 62 epithelial ovarian cancer 62 malignant polyps 62 etanercept Enbrel 62 Dasatinib 62 voriconazole 62 dosage regimens 62 metastatic bladder 62 SPRYCEL ® 62 BENICAR HCT 62 hematopoietic cancers 62 Aflibercept 62 invasive aspergillosis 62 ethambutol 62 refractory chronic lymphocytic 62 prospectively defined 62 iniparib BSI 62 pegylated interferon alpha 62 B CLL 62 Telintra 62 alpha blocker 62 β blockers 62 clodronate 62 active comparator 62 ARICEPT 62 anterior uveitis 62 node metastases 62 FluCAM arm 62 intravitreal injections 62 decitabine 62 debulking surgery 62 concurrent chemoradiation 62 placebo dexamethasone 62 TEAEs 62 Ranibizumab 62 posterior uveitis 62 tacrolimus ointment 62 Metastatic breast cancer 62 Zytiga 62 Tasigna nilotinib 62 GLIADEL R Wafer 62 Lenalidomide 62 IMA# 62 metastatic carcinoma 62 mcg doses 62 ribavirin RBV 62 EFAPROXYN 62 Capecitabine 62 cytologically confirmed 62 cisplatin vinorelbine 62 Adenomas 62 capecitabine Xeloda 62 paricalcitol 62 tipranavir ritonavir 62 imatinib mesylate Gleevec 62 pegylated interferon alfa 2a 62 pediatric malignancies 62 CRVO 62 mCRC 62 histologies 62 canakinumab 62 recurrent VTE 62 homozygous familial hypercholesterolemia 62 Camptosar ® 62 poor metabolizers 62 malignant neoplasm 62 dalteparin 62 SLNB 62 sorafenib 62 PAOD 62 hormone receptor positive 62 unresectable stage 62 COMBIVIR 62 FOLFIRI alone 62 aldosterone antagonist 62 choroidal neovascularization 62 QT QTc 62 refractory NSCLC 62 Cardiotoxicity 62 EDEMA3 62 Peginterferon alfa 2b 62 taxane therapy 62 evaluable subjects 62 BCG refractory 62 ELACYT 62 oral allopurinol 62 p# biomarker 62 Tavocept 62 adecatumumab 62 myelofibrosis polycythemia vera 62 vinca alkaloids 62 meningiomas 62 papillary renal cell carcinoma 62 transaminase elevations 62 liposomal doxorubicin 62 Natalizumab 62 azacitidine 62 familial amyloidotic polyneuropathy FAP 62 urine cytology 62 ACTEMRA TM 62 aspirin clopidogrel 62 metaglidasen 62 CYPHER Stent 62 histological subtypes 62 PROCRIT 62 Herceptin trastuzumab 62 advanced neoplasia 61 lupus nephritis 61 EGFR mutation 61 Thalomid ® 61 alkylating agents 61 prednisone prednisolone 61 EBRT 61 AA Amyloidosis 61 corticosteroid therapy 61 CHAMPION PCI 61 NMIBC 61 tumor histology 61 riociguat 61 oral antidiabetic agents 61 highly emetogenic 61 thalidomide Thalomid 61 Adjuvant chemotherapy 61 Genasense ® 61 ARIMIDEX 61 relapsed ovarian cancer 61 deferiprone 61 dasatinib 61 epoetin alpha 61 brain metastases 61 tamoxifen Nolvadex ® 61 ANCHOR trial 61 transurethral resection 61 adalimumab 61 Fludarabine 61 relapsing remitting MS RRMS 61 verteporfin 61 FOLPI 61 generation purine nucleoside 61 Temsirolimus 61 glioblastoma multiforme GBM 61 FOLFOX 61 ALA PDT 61 nevirapine Viramune 61 AMEVIVE 61 interferon alfa 2a 61 locoregional recurrence 61 dirucotide 61 xanthine oxidase inhibitor 61 NSCLC 61 Gleevec imatinib 61 serous ovarian cancer 61 pioglitazone HCl 61 metastatic HER2 negative 61 RoACTEMRA 61 tumor xenograft models 61 Zevalin consolidation 61 recurrent DVT 61 GnRH agonists 61 endometrial hyperplasia 61 cell lymphoma CTCL 61 REMICADE ® 61 mucinous 61 TNF antagonist 61 cytopenias 61 amphotericin B 61 sleeve lobectomy 61 adriamycin 61 colorectal adenoma 61 LEUKINE 61 Follicular Lymphoma 61 dasatinib Sprycel 61 hepatitis C genotype 61 Avastin bevacizumab 61 metastatic kidney 61 GnRH agonist 61 chronic lymphocytic leukemia CLL 61 CYPHER R Sirolimus eluting 61 imatinib Gleevec ® 61 MERLIN TIMI 61 urothelial carcinoma 61 fluticasone salmeterol 61 recurrent glioblastoma 61 HES CEL 61 CIMZIA TM 61 nab paclitaxel 61 HER2 positive cancers 61 Papillary 61 venlafaxine Effexor 61 Palifosfamide 61 renal insufficiency 61 guaiac 61 refractory CTCL 61 bosutinib 61 LEVAQUIN 61 prostate cancer CRPC 61 #.#ng/ml 61 STRIDE PD 61 rotigotine transdermal patch 61 revascularization procedures 61 Aptivus 61 Bevacizumab Avastin 61 decompensated liver disease 61 histone deacetylase HDAC inhibitor 61 MCyR 61 IL# PE#QQR 61 obscure gastrointestinal bleeding 61 refractory gout 61 adalimumab Humira 61 SUTENT 61 intravesical infusion therapy 61 Femara letrozole 61 anthracycline therapy 61 interferon alfa 2b 61 biologic therapy 61 Pegasys ® 61 low dose Iluvien 61 trastuzumab DM1 T DM1 61 gemcitabine cisplatin 61 renal tumors 61 Elidel 61 systemic lupus erythematosus SLE 61 EURIDIS 61 HRPC 61 hormone LHRH agonist 61 castrate resistant prostate cancer 61 colon capsule endoscopy 61 FFR measurements 61 antithrombotics 61 squamous cell lung cancer 61 plus dexamethasone 61 TAXOTERE ® 61 pegylated interferons 61 chronic ITP patients 61 acute GvHD 61 anemia hemoglobin 61 cisplatin gemcitabine 61 pharmacologically active isomer 61 eosinophilic asthma 61 Eloxatin ® 61 deep venous thromboses 61 Vfend 61 KRAS mutations 61 intravesical therapy 61 docetaxel Taxotere R 61 biochemical relapse 61 INVEGA ® 61 metastatic pancreatic 61 doxorubicin docetaxel 61 recurrent ovarian cancer 61 underwent surgical resection 61 5 fluorouracil 61 keloid scarring 61 sorafenib Nexavar ® 61 INVANZ 61 SUVmax 61 Intravitreal injections 61 myelodysplastic syndromes 61 autoantibody positive 61 rizatriptan 61 sirolimus eluting stents 61 LOVENOX R 61 IXEMPRA 61 Kepivance 61 colorectal carcinomas 61 untreated multiple myeloma 61 phase IIb study 61 erlotinib Tarceva 61 irbesartan 61 remission induction 61 Taxol ® 61 amoxicillin clavulanate 61 KRAS mutation 61 REMINYL ® 61 cetuximab 61 Radical prostatectomy 61 iodixanol 61 exemestane Aromasin 61 Phase III randomized controlled 61 Fibrillex TM 61 follicular thyroid cancer 61 potentially hepatotoxic 61 Quinamed 61 reduce serum phosphate 61 ovarian carcinoma 61 smoldering multiple myeloma 61 cabazitaxel 61 nicardipine 61 BR.# 61 XELOX 61 mg Proellex 61 Neoadjuvant 61 Octreolin 61 herpetic keratitis 61 aldosterone antagonists 61 mycophenolic acid 61 idarubicin 61 SIR Spheres 61 achieved ACR# 61 acute leukemias 61 carcinoids 61 rt PA 61 pegylated interferon alfa 61 Gleevec imatinib mesylate 61 Dacogen injection 61 paroxysmal AF 61 XIENCE V stent 61 grade gliomas 61 pT3 61 anthracycline chemotherapy 61 oxaliplatin Eloxatin 61 colorectal neoplasms 61 EGFR expressing 61 Peginterferon 61 #mg q8h 61 sipuleucel T 61 visilizumab 61 Gemcitabine 61 Cloretazine 61 Voreloxin 61 Vandetanib 61 PROMACTA 61 warfarin therapy 61 Kamada AAT 61 rFSH 61 daunorubicin 61 Sorafenib 61 Ozarelix 61 complement inhibitor eculizumab 61 ximelagatran 61 adenoma recurrence 61 antithrombotic therapy 61 axillary lymph node 61 ixabepilone 61 Alemtuzumab 61 chronic HBV 61 MYCAMINE 61 micafungin 61 chronic plaque psoriasis 61 FUSILEV enhances 61 SNT MC# 61 chronic HCV infection 61 OncoVEX GM CSF 61 IMiDs ® compound 61 Sutent sunitinib 61 BCG refractory carcinoma 61 drotrecogin alfa activated 61 KETEK 61 patients undergoing percutaneous 61 aflibercept 61 AZOR 61 PD LID 61 asymptomatic carotid stenosis 61 phase IIb trial 61 HuMax EGFr 61 imatinib Gleevec 61 TG# [003] 61 anagrelide 60 superficial basal cell carcinoma 60 TELINTRA 60 postmenopausal osteoporotic women 60 Metastatic Colorectal Cancer 60 EUS FNA 60 tyrosine kinase inhibitors TKIs 60 Pegasys peginterferon alfa 2a 60 APTIVUS 60 plus prednisone 60 ruboxistaurin 60 urothelial bladder cancer 60 ranibizumab Lucentis 60 Warfarin Coumadin 60 symptomatic paroxysmal AF 60 paroxetine Paxil 60 unstable angina UA 60 hematologic disorders 60 minimally symptomatic 60 placebo controlled clinical 60 Hormone Refractory Prostate Cancer 60 nonmetastatic prostate cancer 60 DU #b 60 evaluating REVLIMID 60 Vidaza azacitidine 60 PSMA ADC 60 Decitabine 60 intestinal metaplasia 60 squamous cell cancers 60 alvespimycin 60 situ LCIS 60 overt nephropathy 60 ibandronate 60 palifermin 60 invasive ductal 60 non splenectomized 60 gastric adenocarcinoma 60 acetonide FA 60 K ras mutations 60 Thrombolysis 60 epirubicin 60 fosamprenavir 60 Flu Cy 60 HGPIN 60 angiographic outcomes 60 laser photocoagulation 60 ß blockers 60 bexarotene 60 Zolinza 60 Mylotarg 60 tumor recurrence 60 quetiapine Seroquel 60 renal cell carcinomas 60 autologous SCT 60 relapsed refractory multiple myeloma 60 glufosfamide 60 lymphoma CTCL 60 Azedra 60 myelofibrosis MF 60 Candesartan 60 PREZISTA rtv 60 serum prostate 60 squamous non 60 HSCT 60 AGILECT ® 60 intravenous dosing 60 salmeterol inhalation powder 60 trimethoprim sulfamethoxazole 60 gefitinib 60 AZILECT R 60 thrombocytopenic 60 castration resistant prostate cancer 60 eribulin 60 acute STEMI 60 YERVOY 60 rALLy 60 PRECiSE 60 brivaracetam 60 medullary thyroid cancer 60 leukopenia 60 cervical intraepithelial neoplasia 60 HepaSphere 60 temsirolimus Torisel ® 60 squamous cell 60 PANVAC VF 60 mitomycin 60 BARACLUDE R 60 relapsing multiple sclerosis 60 myeloproliferative diseases 60 ertapenem 60 Raptiva R 60 mcg QD 60 interferon beta 1a 60 lymph node dissection 60 lenalidomide dexamethasone 60 custirsen 60 undergone radical prostatectomy 60 rilonacept 60 Recurrence Score 60 catheter angiography 60 CoFactor 60 Motesanib 60 virological failure 60 Aplidin 60 Naive Patients 60 Castration Resistant Prostate Cancer 60 pancreatic carcinoma 60 Bezielle 60 non squamous histology 60 antihypertensive therapy 60 nucleoside analog 60 hereditary deficiency 60 sunitinib Sutent 60 TACE 60 Allovectin 7 60 aripiprazole Abilify 60 solar keratoses 60 Vectibix panitumumab 60 Epoetin alfa 60 CLARITY study 60 generalized edema 60 heavily pretreated 60 VIDAZA 60 renal impairment 60 TheraSphere 60 antiepileptic drug 60 topotecan 60 endarterectomy 60 Cetuximab Erbitux 60 mg/m2 dose 60 anthracycline containing 60 AVONEX ® 60 droperidol 60 stenoses 60 aminotransferases 60 corticosteroid dexamethasone 60 pertuzumab 60 neoplasm 60 antiarrhythmic drug 60 polyp recurrence 60 metastatic squamous cell carcinoma 60 allogeneic stem cell 60 NovoTTF 60 diagnosed multiple myeloma 60 Camptosar 60 ADPKD 60 leukemia ALL 60 beta2 agonist 60 Dabigatran 60 GW# [003] 60 vemurafenib 60 prospective multicenter study 60 Interferon alfa 60 Pegintron 60 lopinavir r 60 beclomethasone dipropionate 60 BRIM3 60 dose cohort 60 relapsed multiple myeloma 60 myelodysplastic syndromes MDS 60 5 fluorouracil leucovorin 60 neratinib 60 leucovorin 60 Seliciclib 60 R sorafenib tablets 60 sentinel lymph node biopsy 60 COPAXONE R 60 pegylated interferon alfa 2b 60 sertraline Zoloft 60 percutaneous transluminal coronary angioplasty 60 Acute Coronary Syndromes ACS 60 refractory Hodgkin lymphoma 60 liposomal amphotericin B 60 Navelbine 60 pemetrexed 60 neoplasia 60 Pegasys plus Copegus 60 colorectal neoplasia 60 Eli Lilly Gemzar 60 hepatotoxicity 60 vinca alkaloid 60 miconazole Lauriad ® 60 Metastatic Prostate Cancer 60 FOLPI regimen 60 chemotherapy regimens 60 nodal metastasis 60 Phase #/#a trial 60 cardiotoxicity 60 Glufosfamide 60 nilotinib 60 pCR 60 cytoreductive surgery 60 TRISENOX 60 trials RCTs 60 portal vein thrombosis 60 NYHA Class III 60 indolent NHL 60 cardioembolic stroke 60 letrozole Femara 60 lymph node involvement 60 pituitary adenomas 60 elacytarabine 60 NYHA Class II 60 pelvic lymphadenectomy 60 Protopic 60 metastatic malignant melanoma 60 calcineurin inhibitor 60 Lung transplantation